12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Relovair fluticasone furoate/vilanterol: Phase III data

Top-line data from a double-blind, Phase III trial in about 2,000 patients with moderate to severe asthma showed that 100/25 µg Relovair fluticasone furoate/vilanterol met the primary endpoint of superiority in increasing time to first asthma exacerbation vs. 100 ug fluticasone furoate alone (p=0.036). Relovair also met the secondary endpoint...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >